GLP-2 (Glepaglutide)

Quick Facts

Introduction

Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid intestinotrophic hormone of the glucagon/secretin superfamily, secreted by intestinal L-cells alongside its better-known sibling GLP-1. Where GLP-1 research centers on glucose and appetite, GLP-2 research centers on the growth and maintenance of the intestinal lining — making it a defining molecule in the study of intestinal adaptation and recovery.

Glepaglutide is a long-acting synthetic GLP-2 analogue engineered to resist the rapid enzymatic degradation that limits the native hormone. It belongs to the same class as teduglutide, an established GLP-2 analogue studied for short bowel syndrome. Together these compounds illustrate the research strategy of converting a short-lived gut hormone into a durable tool for studying mucosal growth, a theme catalogued across the peptide database.

This profile covers what GLP-2 is, the structural modifications that make analogues like glepaglutide long-acting, its GLP-2 receptor mechanism, the intestinal-adaptation research it appears in, and how it compares with related compounds including teduglutide and the barrier-focused peptide Larazotide Acetate. It is one of the more clinically studied recovery peptides in this catalogue.

What is GLP-2 (Glepaglutide)?

GLP-2 is a proglucagon-derived peptide released from intestinal L-cells in response to nutrient intake. Its principal documented role is intestinotrophic — it promotes growth and maintenance of the intestinal epithelium, increasing the absorptive surface area of the gut. Native GLP-2, however, is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), giving it a half-life of only minutes and limiting its usefulness as a research or therapeutic tool.

Glepaglutide is a synthetic GLP-2 analogue designed to overcome that limitation through sequence modifications that increase stability and prolong activity. It has been studied in clinical research, including trials in short bowel syndrome — a condition of inadequate intestinal absorption — where increasing absorptive capacity is the central goal. This places glepaglutide in the same research lineage as teduglutide, the first GLP-2 analogue to be developed for that setting.

Molecular and structural characteristics

Native GLP-2 is a linear 33-residue peptide that, like other members of the glucagon/secretin family, adopts a helical conformation when engaging its receptor. A key vulnerability lies at its N-terminus, where DPP-4 cleaves the peptide and inactivates it — the same enzymatic liability seen with GLP-1 and other incretin-family peptides.

Long-acting analogues address this through stabilizing modifications. Teduglutide, for example, carries a single amino-acid substitution near the N-terminus that confers DPP-4 resistance, while glepaglutide is engineered with sequence changes that extend its duration further, supporting less frequent administration in research settings. The central design principle across the class is converting a minutes-long signal into a sustained one without losing GLP-2 receptor activity.

Mechanism of action

GLP-2 acts through the GLP-2 receptor (GLP-2R), a G-protein-coupled receptor expressed on specific cell populations in the intestine, including enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons. Notably, GLP-2R is not expressed directly on the absorptive enterocytes that proliferate; instead, receptor activation triggers release of downstream mediators — including insulin-like growth factor-1 (IGF-1), keratinocyte growth factor, and other trophic and vascular signals — that drive the observed mucosal effects.

Through this indirect, mediator-driven mechanism, GLP-2 is associated with crypt-cell proliferation and villus growth, expanding the intestinal absorptive surface. It is additionally studied for reduced epithelial apoptosis, enhanced mucosal blood flow, and effects on barrier function and gut motility. The net research theme is intestinal adaptation — the gut's capacity to remodel and increase its absorptive capacity.

This mechanism contrasts instructively with that of its relative GLP-1: both are proglucagon-derived and engage GPCRs, but GLP-1 receptor agonists are studied for glucose and appetite, whereas GLP-2 is studied for gut tissue growth. It also contrasts with barrier-focused peptides like Larazotide Acetate, which regulate permeability rather than promote growth.

• Agonism at the GLP-2 receptor on non-enterocyte intestinal cells.
• Release of downstream mediators (IGF-1, KGF) that drive mucosal growth.
• Stimulation of crypt-cell proliferation and villus elongation.
• Reduced epithelial apoptosis and enhanced mucosal blood flow.
• Net expansion of intestinal absorptive surface area.

Intestinal-adaptation and absorption research

The flagship research context for GLP-2 analogues is short bowel syndrome, a condition in which loss of functional intestine leaves study populations dependent on parenteral nutrition. Because GLP-2 expands absorptive surface area, analogues such as teduglutide and glepaglutide have been studied for their association with reduced dependence on parenteral support — a direct readout of improved intestinal absorption.

Glepaglutide specifically has been examined in clinical trials as a long-acting option intended to allow less frequent administration than earlier analogues. The broader research theme — harnessing an endogenous intestinotrophic hormone to drive gut adaptation — connects GLP-2 to the wider study of recovery-focused peptides catalogued in the peptide database.

Gut-recovery and trophic research

Beyond short bowel syndrome, the intestinotrophic biology of GLP-2 makes it a subject of broader gut-recovery research. Preclinical work has examined GLP-2 in contexts involving mucosal injury and the maintenance of barrier integrity, on the rationale that a healthier, better-developed epithelium supports both absorption and barrier function.

It is important to distinguish GLP-2's growth-promoting action from the barrier-sealing action of permeability regulators. Where Larazotide Acetate is studied for closing tight junctions, GLP-2 is studied for expanding and maintaining the absorptive tissue itself. This trophic property also underlies a key cautionary theme in the research: agents that promote cell proliferation warrant careful study of growth-related risks.

Comparison: GLP-2 (Glepaglutide) vs Teduglutide vs Semaglutide

GLP-2 analogues are best understood alongside teduglutide, the established GLP-2 analogue, and semaglutide, a GLP-1 analogue — a comparison that highlights how two proglucagon-derived peptides diverge in function.

Teduglutide and glepaglutide share the GLP-2 receptor and the goal of intestinal growth, differing mainly in duration of action, while Semaglutide acts on the GLP-1 receptor for entirely different endpoints. Full entries for related compounds are in the peptide database.

Half-life and pharmacokinetic considerations

Native GLP-2 has a half-life of only minutes, owing to rapid DPP-4 cleavage at its N-terminus — the same kinetic limitation seen across the incretin/proglucagon family. This brevity is what made the native hormone impractical and motivated the development of stabilized analogues.

Glepaglutide is engineered for a substantially longer duration of action, supporting less frequent administration in research, while teduglutide occupies an intermediate position. As with other analogue classes, findings from a long-acting analogue should not be assumed to apply identically to the native peptide, so the literature distinguishes carefully between them.

Reconstitution and handling considerations

Lyophilized GLP-2 or glepaglutide is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken to protect the peptide. The resulting solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized GLP-2 / glepaglutide is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled through freeze–thaw.

Research limitations

GLP-2 analogues are research compounds whose clinical study has concentrated on short bowel syndrome and intestinal adaptation. Because the mechanism is fundamentally growth-promoting, the research emphasizes careful evaluation of proliferation-related risks, and findings in specific study populations cannot be generalized. Native GLP-2's very short half-life further means results are highly form- and analogue-dependent. It is described here strictly for research reference.

• Clinical research has focused mainly on short bowel syndrome.
• The trophic (growth-promoting) mechanism warrants careful risk evaluation.
• Results are strongly analogue- and form-dependent (native vs long-acting).
• It is not an approved therapy in this context and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014.Source
2. Naimi RM, et al. Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019.Source
3. Jeppesen PB, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012.Source